

# Jennifer H Martin

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/6517731/jennifer-h-martin-publications-by-year.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

209  
papers

5,566  
citations

38  
h-index

69  
g-index

248  
ext. papers

6,782  
ext. citations

3.8  
avg, IF

6.06  
L-index

#	Paper	IF	Citations
209	"LONG COVID"-A hypothesis for understanding the biological basis and pharmacological treatment strategy.. <i>Pharmacology Research and Perspectives</i> , <b>2022</b> , 10, e00911	3.1	10
208	Systems analysis shows that thermodynamic physiological and pharmacological fundamentals drive COVID-19 and response to treatment.. <i>Pharmacology Research and Perspectives</i> , <b>2022</b> , 10, e00922	3.1	4
207	The interacting physiology of COVID-19 and the renin-angiotensin-aldosterone system: Key agents for treatment.. <i>Pharmacology Research and Perspectives</i> , <b>2022</b> , 10, e00917	3.1	9
206	Expert advice for prescribing cannabis medicines for patients with epilepsy-drawn from the Australian clinical experience.. <i>British Journal of Clinical Pharmacology</i> , <b>2022</b> ,	3.8	2
205	Melanoma: An immunotherapy Journey from bench to bedside.. <i>Cancer Treatment and Research</i> , <b>2022</b> , 183, 49-89	3.5	
204	Patient-oriented medication education intervention has long-term benefits for people with decompensated cirrhosis.. <i>Hepatology Communications</i> , <b>2022</b> ,	6	0
203	Measurement of 5- fluorouracil, capecitabine and its metabolite concentrations in blood using volumetric absorptive microsampling technology and LC-MS/MS. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , <b>2021</b> , 1188, 123075	3.2	0
202	Unraveling the complexity of therapeutic drug monitoring for monoclonal antibody therapies to individualize dose in oncology. <i>Pharmacology Research and Perspectives</i> , <b>2021</b> , 9, e00757	3.1	4
201	Easier patient access to medical cannabis carries risks as well as benefits. <i>Journal of Psychopharmacology</i> , <b>2021</b> , 35, 1435-1436	4.6	
200	Obesity and COVID-19: Renin-Angiotensin as a mediator of morbidity and mortality. <i>British Journal of Nutrition</i> , <b>2021</b> , 1-6	3.6	2
199	Repurposing existing therapeutics, its importance in oncology drug development: Kinases as a potential target. <i>British Journal of Clinical Pharmacology</i> , <b>2021</b> ,	3.8	4
198	A pharmacological framework for integrating treating the host, drug repurposing and the damage response framework in COVID-19. <i>British Journal of Clinical Pharmacology</i> , <b>2021</b> , 87, 875-885	3.8	4
197	Overcoming barriers to implementing precision dosing with 5-fluorouracil and capecitabine. <i>British Journal of Clinical Pharmacology</i> , <b>2021</b> , 87, 317-325	3.8	2
196	Evaluation of pharmacogenomics and hepatic nuclear imaging-related covariates by population pharmacokinetic models of irinotecan and its metabolites. <i>European Journal of Clinical Pharmacology</i> , <b>2021</b> , 1	2.8	0
195	Therapeutic drug monitoring in oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology consensus guidelines for imatinib therapy. <i>European Journal of Cancer</i> , <b>2021</b> , 157, 428-440	7.5	4
194	Pharmacokinetics, Safety, and Tolerability of a Medicinal Cannabis Formulation in Patients with Chronic Non-cancer Pain on Long-Term High Dose Opioid Analgesia: A Pilot Study.. <i>Pain and Therapy</i> , <b>2021</b> , 11, 171	3.6	1
193	Drug repurposing in the era of COVID-19: a call for leadership and government investment. <i>Medical Journal of Australia</i> , <b>2020</b> , 212, 450-452.e1	4	8

192	Effect of pharmaceutical regulatory policy on health impact. <i>British Journal of Clinical Pharmacology</i> , <b>2020</b> , 86, 2335-2337	3.8	1
191	Endocytosis Inhibition in Humans to Improve Responses to ADCC-Mediating Antibodies. <i>Cell</i> , <b>2020</b> , 180, 895-914.e27	56.2	45
190	Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: a double-blind, placebo-controlled, randomised clinical trial of efficacy and safety of 1:1 delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD). <i>Trials</i> , <b>2020</b> , 21, 611	2.8	9
189	Buying time: Drug repurposing to treat the host in COVID-19H. <i>Pharmacology Research and Perspectives</i> , <b>2020</b> , 8, e00620	3.1	4
188	Inability of Current Dosing to Achieve Carboplatin Therapeutic Targets in People with Advanced Non-Small Cell Lung Cancer: Impact of Systemic Inflammation on Carboplatin Exposure and Clinical Outcomes. <i>Clinical Pharmacokinetics</i> , <b>2020</b> , 59, 1013-1026	6.2	2
187	Barriers and Challenges in Performing Pharmacokinetic Studies to Inform Dosing in the Neonatal Population. <i>Pharmacy (Basel, Switzerland)</i> , <b>2020</b> , 8,	2	4
186	Preoperative cisplatin, fluorouracil, and docetaxel with or without radiotherapy after poor early response to cisplatin and fluorouracil for resectable oesophageal adenocarcinoma (AGITG DOCTOR): results from a multicentre, randomised controlled phase II trial. <i>Annals of Oncology</i> , <b>2020</b> 31, 236-245.	10.3	19
185	Communication, Collaboration and Care Coordination: The Three-Point Guide to Cancer Care Provision for Aboriginal and Torres Strait Islander Australians. <i>International Journal of Integrated Care</i> , <b>2020</b> , 20, 10	2	2
184	On strongly unimodal third-order SISO linear systems with applications to pharmacokinetics. <i>IFAC-PapersOnLine</i> , <b>2020</b> , 53, 4654-4661	0.7	
183	Vancomycin therapeutic drug monitoring in paediatrics. <i>Journal of Paediatrics and Child Health</i> , <b>2020</b> , 56, 563-570	1.3	6
182	Using Therapeutic Drug Monitoring and Pharmacovigilance to Overcome Some of the Challenges of Developing Medicinal Cannabis from Botanical Origins. <i>Therapeutic Drug Monitoring</i> , <b>2020</b> , 42, 98-101	3.2	1
181	"I'm a Survivor": Aboriginal and Torres Strait Islander Cancer Survivors' Perspectives of Cancer Survivorship. <i>Cancer Nursing</i> , <b>2020</b> , 43, 105-114	2.6	4
180	Vancomycin: Audit of American guideline-based intermittent dose administration with focus on overweight patients. <i>British Journal of Clinical Pharmacology</i> , <b>2020</b> , 86, 958-965	3.8	4
179	Effectiveness of patient-oriented education and medication management intervention in people with decompensated cirrhosis. <i>Internal Medicine Journal</i> , <b>2020</b> , 50, 1142-1146	1.6	2
178	Clinical trials with cannabis medicines-guidance for ethics committees, governance officers and researchers to streamline ethics applications and ensuring patient safety: considerations from the Australian experience. <i>Trials</i> , <b>2020</b> , 21, 932	2.8	4
177	Science and art of anticancer drug dosing: nine steps to personalised therapy. <i>Internal Medicine Journal</i> , <b>2020</b> , 50, 992-996	1.6	
176	Are general practitioners getting the information they need from hospitals and specialists to provide quality cancer care for Indigenous Australians?. <i>Internal Medicine Journal</i> , <b>2020</b> , 50, 38-47	1.6	
175	Model-based analysis on systemic availability of co-administered cannabinoids after controlled vaporised administration. <i>Internal Medicine Journal</i> , <b>2020</b> , 50, 846-853	1.6	5

174	Patterns of primary health care service use of Indigenous Australians diagnosed with cancer. <i>Supportive Care in Cancer</i> , <b>2020</b> , 28, 317-327	3.9	4
173	Translational hurdles with cannabis medicines. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2020</b> , 29, 1325-1330	3	
172	Intensive lipid-lowering therapy in the 12 months after an acute coronary syndrome in Australia: an observational analysis. <i>Medical Journal of Australia</i> , <b>2019</b> , 211, 284-284.e1	4	0
171	Clinically Optimal Versus "Target" Doses in Heart Failure. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 74, 1425	15.1	
170	Systematic review of interventions to improve safety and quality of anticoagulant prescribing for therapeutic indications for hospital inpatients. <i>European Journal of Clinical Pharmacology</i> , <b>2019</b> , 75, 1645-1657	2.8	2
169	Drug-Induced Liver Injury due to Flucloxacillin: Relevance of Multiple Human Leukocyte Antigen Alleles. <i>Clinical Pharmacology and Therapeutics</i> , <b>2019</b> , 106, 245-253	6.1	35
168	A randomised controlled trial of vaporised tetrahydrocannabinol and cannabidiol alone and in combination in frequent and infrequent cannabis users: acute intoxication effects. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , <b>2019</b> , 269, 17-35	5.1	92
167	Efficacy and toxicity of antihypertensive pharmacotherapy relative to effective dose 50. <i>British Journal of Clinical Pharmacology</i> , <b>2019</b> , 85, 2218-2227	3.8	5
166	The rationale of dose-response curves in selecting cancer drug dosing. <i>British Journal of Clinical Pharmacology</i> , <b>2019</b> , 85, 2198-2204	3.8	8
165	Unmet supportive care needs among people with cancer: A cross-cultural comparison between Indigenous and Non-Indigenous Australians. <i>European Journal of Cancer Care</i> , <b>2019</b> , 28, e13080	2.4	6
164	Medication-Related Problems in Outpatients With Decompensated Cirrhosis: Opportunities for Harm Prevention. <i>Hepatology Communications</i> , <b>2019</b> , 3, 620-631	6	20
163	A Missense Variant in PTPN22 is a Risk Factor for Drug-induced Liver Injury. <i>Gastroenterology</i> , <b>2019</b> , 156, 1707-1716.e2	13.3	59
162	A Validated Method for the Detection of Synthetic Cannabinoids in Oral Fluid. <i>Journal of Analytical Toxicology</i> , <b>2019</b> , 43, 10-17	2.9	12
161	Weight-based tacrolimus trough concentrations post liver transplant. <i>Internal Medicine Journal</i> , <b>2019</b> , 49, 79-83	1.6	2
160	Spotlight Commentary: Model-informed precision dosing must demonstrate improved patient outcomes. <i>British Journal of Clinical Pharmacology</i> , <b>2019</b> , 85, 2238-2240	3.8	11
159	Cannabinoid use in practice in Australasia-Better guidance and new drug information systems will be essential for prescribers. <i>British Journal of Clinical Pharmacology</i> , <b>2019</b> , 85, 1664-1665	3.8	1
158	Comparative efficacy and safety of immunotherapies targeting the PD-1/PD-L1 pathway for previously treated advanced non-small cell lung cancer: A Bayesian network meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , <b>2019</b> , 142, 16-25	7	17
157	Development of an UHPLC-MS/MS method for remifentanyl quantification in a small plasma volume. <i>Journal of Liquid Chromatography and Related Technologies</i> , <b>2019</b> , 42, 521-527	1.3	

156	Optimising low-dose methotrexate for rheumatoid arthritis-A review. <i>British Journal of Clinical Pharmacology</i> , <b>2019</b> , 85, 2228-2234	3.8	20
155	Reply. <i>Hepatology Communications</i> , <b>2019</b> , 3, 1283-1284	6	
154	Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: a double-blind, placebo controlled, randomised clinical trial of efficacy and safety of cannabidiol (CBD). <i>BMC Palliative Care</i> , <b>2019</b> , 18, 110	3	13
153	DRUG REPURPOSING-Overcoming the translational hurdles to clinical use. <i>Pharmacology Research and Perspectives</i> , <b>2019</b> , 7, e00548	3.1	1
152	Defining and classifying terminology for medication harm: a call for consensus. <i>European Journal of Clinical Pharmacology</i> , <b>2019</b> , 75, 137-145	2.8	20
151	Drug-associated pulmonary arterial hypertension. <i>Clinical Toxicology</i> , <b>2018</b> , 56, 801-809	2.9	25
150	Prolonged Cannabidiol Treatment Effects on Hippocampal Subfield Volumes in Current Cannabis Users. <i>Cannabis and Cannabinoid Research</i> , <b>2018</b> , 3, 94-107	4.6	41
149	Cannabinoid Disposition After Human Intraperitoneal Use: AnInsight Into Intraperitoneal Pharmacokinetic Properties in Metastatic Cancer. <i>Clinical Therapeutics</i> , <b>2018</b> , 40, 1442-1447	3.5	7
148	Second-Hand Exposure of Staff Administering Vaporised Cannabinoid Products to Patients in a Hospital Setting. <i>Drugs in R and D</i> , <b>2018</b> , 18, 41-44	3.4	4
147	Therapeutic Effects of Prolonged Cannabidiol Treatment on Psychological Symptoms and Cognitive Function in Regular Cannabis Users: A Pragmatic Open-Label Clinical Trial. <i>Cannabis and Cannabinoid Research</i> , <b>2018</b> , 3, 21-34	4.6	60
146	Clinical benefits of evolocumab appear less than hoped. <i>Lancet, The</i> , <b>2018</b> , 391, 933-934	4.0	1
145	Lessons learned from a pilot study of an Indigenous patient navigator intervention in Queensland, Australia. <i>European Journal of Cancer Care</i> , <b>2018</b> , 27, e12714	2.4	9
144	Use of complementary and alternative medicines in people with depression and central obesity: Findings from a Tai Chi and Qigong study. <i>Journal of Traditional Chinese Medical Sciences</i> , <b>2018</b> , 5, 100-109	0.6	1
143	Exogenous Cannabinoid Efficacy: Merely a Pharmacokinetic Interaction?. <i>Clinical Pharmacokinetics</i> , <b>2018</b> , 57, 539-545	6.2	22
142	Cannabis contaminants: sources, distribution, human toxicity and pharmacologic effects. <i>British Journal of Clinical Pharmacology</i> , <b>2018</b> , 84, 2468-2476	3.8	53
141	Pharmacovigilance and expedited drug approvals. <i>Australian Prescriber</i> , <b>2018</b> , 41, 50-53	1.4	4
140	Exploring Positive Survivorship Experiences of Indigenous Australian Cancer Patients. <i>International Journal of Environmental Research and Public Health</i> , <b>2018</b> , 15,	4.6	8
139	Community-identified recommendations to enhance cancer survivorship for Aboriginal and Torres Strait Islander people. <i>Australian Journal of Primary Health</i> , <b>2018</b> , 24, 233-240	1.4	7

138	Laxative Use in Inpatients on Oxycodone/Naloxone Prolonged Release and Oxycodone Prolonged Release for Cancer and Non-cancer Pain. <i>Journal of Pain and Palliative Care Pharmacotherapy</i> , <b>2018</b> , 32, 116-123	0.8	2
137	Automated adverse drug reaction detection. <i>Australian Prescriber</i> , <b>2018</b> , 41, 138	1.4	0
136	Gender differences in doxorubicin pharmacology for subjects with chemosensitive cancers of young adulthood. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2018</b> , 82, 887-898	3.5	6
135	Compassion and evidence in prescribing cannabinoids: a perspective from the Royal Australasian College of Physicians. <i>Medical Journal of Australia</i> , <b>2018</b> , 208, 107-109	4	5
134	Gaps in predicting clinical doses for cannabinoids therapy: Overview of issues for pharmacokinetics and pharmacodynamics modelling. <i>British Journal of Clinical Pharmacology</i> , <b>2018</b> , 84, 2483-2487	3.8	15
133	Lipid and other management to improve arterial disease and survival in end stage renal disease. <i>Expert Opinion on Pharmacotherapy</i> , <b>2017</b> , 18, 343-349	4	2
132	Follow-up cancer care: perspectives of Aboriginal and Torres Strait Islander cancer survivors. <i>Supportive Care in Cancer</i> , <b>2017</b> , 25, 1597-1605	3.9	13
131	Exploratory study into the unmet supportive needs of people diagnosed with cirrhosis in Queensland, Australia. <i>Internal Medicine Journal</i> , <b>2017</b> , 47, 429-435	1.6	13
130	Individualised medicine: why we need Bayesian dosing. <i>Internal Medicine Journal</i> , <b>2017</b> , 47, 593-600	1.6	28
129	Introduction. <i>Internal Medicine Journal</i> , <b>2017</b> , 47, 157-158	1.6	
128	Ezetimibe: Use, costs, and adverse events in Australia. <i>Cardiovascular Therapeutics</i> , <b>2017</b> , 35, 40-46	3.3	8
127	Safety and efficacy of statins. <i>Lancet, The</i> , <b>2017</b> , 389, 1098	4.0	3
126	Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study. <i>Gastroenterology</i> , <b>2017</b> , 152, 1078-1089	13.3	137
125	Persistence of DNA adducts, hypermutation and acquisition of cellular resistance to alkylating agents in glioblastoma. <i>Cancer Biology and Therapy</i> , <b>2017</b> , 18, 917-926	4.6	7
124	Comment on a paper by Dupouiron et al. "A phase III randomized controlled study on the efficacy and improved bowel function of prolonged-release (PR) oxycodone-naloxone (up to 160/80mg daily) versus oxycodone PR". <i>European Journal of Pain</i> , <b>2017</b> , 21, 1772-1773	3.7	
123	Patient-oriented education and medication management intervention for people with decompensated cirrhosis: study protocol for a randomized controlled trial. <i>Trials</i> , <b>2017</b> , 18, 339	2.8	10
122	Pharmacokinetic-Guided Dosing of New Oral Cancer Agents. <i>Journal of Clinical Pharmacology</i> , <b>2017</b> , 57 Suppl 10, S78-S98	2.9	19
121	Predicting drug interactions in addiction treatment. <i>Internal Medicine Journal</i> , <b>2017</b> , 47, 872-878	1.6	1

120	Optimising care of patients with chronic disease: patient-oriented education may improve disease knowledge and self-management. <i>Internal Medicine Journal</i> , <b>2017</b> , 47, 952-955	1.6	14
119	A Validated Method for the Detection of 32 Bath Salts in Oral Fluid. <i>Journal of Analytical Toxicology</i> , <b>2017</b> , 41, 659-669	2.9	19
118	Identification of Australian Aboriginal and Torres Strait Islander Cancer Patients in the Primary Health Care Setting. <i>Frontiers in Public Health</i> , <b>2017</b> , 5, 199	6	6
117	A Simple and Sensitive LC-MS/MS Method for the Simultaneous Determination of Cyclophosphamide and Doxorubicin Concentrations in Human Plasma. <i>Current Pharmaceutical Analysis</i> , <b>2017</b> , 14,	0.6	1
116	The challenge of discharge: combining medication reconciliation and discharge planning. <i>Medical Journal of Australia</i> , <b>2017</b> , 206, 20-21	4	1
115	Precision dosing of targeted anticancer drugs—challenges in the real world. <i>Translational Cancer Research</i> , <b>2017</b> , 6, S1500-S1511	0.3	9
114	The Development of a Rapid, Simple and Sensitive LC-MS/MS Method, to Guide Clinical Dosing, for the Analysis of 5-Fluorouracil in Human Plasma. <i>Current Pharmaceutical Analysis</i> , <b>2017</b> , 13,	0.6	1
113	Medication beliefs predict medication adherence in ambulatory patients with decompensated cirrhosis. <i>World Journal of Gastroenterology</i> , <b>2017</b> , 23, 7321-7331	5.6	15
112	Breast cancer diagnosis, patterns of care and burden of disease in Queensland, Australia (1998-2004): does being Indigenous make a difference?. <i>International Journal of Public Health</i> , <b>2016</b> , 61, 435-42	4	11
111	Clinical trials of medicinal cannabis for appetite-related symptoms from advanced cancer: a survey of preferences, attitudes and beliefs among patients willing to consider participation. <i>Internal Medicine Journal</i> , <b>2016</b> , 46, 1269-1275	1.6	18
110	Trading Lower HbA1c for Increased Adverse Events: A Zero Sum Game?. <i>Journal of the American College of Cardiology</i> , <b>2016</b> , 68, 1372-3	15.1	
109	Prevalence of medication discrepancies in patients with cirrhosis: a pilot study. <i>BMC Gastroenterology</i> , <b>2016</b> , 16, 114	3	20
108	Off-label use of tumour necrosis factor-alpha inhibitors and anakinra at an Australian tertiary hospital. <i>Internal Medicine Journal</i> , <b>2016</b> , 46, 1386-1391	1.6	1
107	How Optimal are Optimal Sampling Times for Tyrosine Kinase Inhibitors in Cancer? Practical Considerations. <i>Clinical Pharmacokinetics</i> , <b>2016</b> , 55, 1171-1177	6.2	4
106	Health-related quality of life among Indigenous Australians diagnosed with cancer. <i>Quality of Life Research</i> , <b>2016</b> , 25, 1999-2008	3.7	12
105	Rural-urban disparities in stage of breast cancer at diagnosis in Australian women. <i>Australian Journal of Rural Health</i> , <b>2016</b> , 24, 326-332	1.3	6
104	Health professional perspectives of the barriers and enablers to cancer care for Indigenous Australians. <i>European Journal of Cancer Care</i> , <b>2016</b> , 25, 254-61	2.4	11
103	Determination of a suitable voriconazole pharmacokinetic model for personalised dosing. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , <b>2016</b> , 43, 165-77	2.7	9

102	Repurposing some older drugs that cross the blood-brain barrier and have potential anticancer activity to provide new treatment options for glioblastoma. <i>British Journal of Clinical Pharmacology</i> , <b>2016</b> , 81, 199-209	3.8	31
101	Achieving the World Health Organization's vision for clinical pharmacology. <i>British Journal of Clinical Pharmacology</i> , <b>2016</b> , 81, 223-7	3.8	10
100	Pharmacokinetics of Cannabis in Cancer Cachexia-Anorexia Syndrome. <i>Clinical Pharmacokinetics</i> , <b>2016</b> , 55, 807-812	6.2	26
99	The hazards of rapid approval of new drugs. <i>Australian Prescriber</i> , <b>2016</b> , 39, 2-3	1.4	4
98	The challenge of costly drugs. <i>Australian Prescriber</i> , <b>2016</b> , 39, 72-4	1.4	1
97	The challenge of costly drugs. <i>Australian Prescriber</i> , <b>2016</b> , 39, 149	1.4	
96	Medicinal cannabis in Australia: the missing links. <i>Medical Journal of Australia</i> , <b>2016</b> , 204, 371-3	4	11
95	Diagnostic errors in older patients: a systematic review of incidence and potential causes in seven prevalent diseases. <i>International Journal of General Medicine</i> , <b>2016</b> , 9, 137-46	2.3	45
94	Issues of Pharmacogenomics in Monitoring Warfarin Therapy <b>2016</b> , 261-277		
93	Medicinal cannabis in Australia: the missing links. <i>Medical Journal of Australia</i> , <b>2016</b> , 205, 425	4	
92	Monte Carlo simulations of the clinical benefits from therapeutic drug monitoring of sunitinib in patients with gastrointestinal stromal tumours. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2016</b> , 78, 209-16	3.5	18
91	Valproate in Adjuvant Glioblastoma Treatment. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 3105-7	2.2	11
90	Evaluation of therapeutic enoxaparin in a pregnant population at a tertiary hospital. <i>Internal Medicine Journal</i> , <b>2016</b> , 46, 826-33	1.6	6
89	The role of the GP in follow-up cancer care: a systematic literature review. <i>Journal of Cancer Survivorship</i> , <b>2016</b> , 10, 990-1011	5.1	60
88	The Impact of Model-Misspecification on Model Based Personalised Dosing. <i>AAPS Journal</i> , <b>2016</b> , 18, 1244-1253	3.7	33
87	Medicines optimisation in older people: Taking age and sex into account. <i>Maturitas</i> , <b>2016</b> , 93, 114-120	5	9
86	Can paracetamol (acetaminophen) be administered to patients with liver impairment?. <i>British Journal of Clinical Pharmacology</i> , <b>2016</b> , 81, 210-22	3.8	48
85	The effect of valproic acid in combination with irradiation and temozolomide on primary human glioblastoma cells. <i>Journal of Neuro-Oncology</i> , <b>2015</b> , 122, 263-71	4.8	38



84	Where is the radiobiology and pharmacology research to improve outcomes in glioblastoma?. <i>Journal of Neuro-Oncology</i> , <b>2015</b> , 124, 1-3	4.8	3
83	Clinical consequences of a miscalibrated digoxin immunoassay. <i>Therapeutic Drug Monitoring</i> , <b>2015</b> , 37, 104-9	3.2	2
82	Reducing inappropriate polypharmacy: the process of deprescribing. <i>JAMA Internal Medicine</i> , <b>2015</b> , 175, 827-34	11.5	722
81	Systematic review: unmet supportive care needs in people diagnosed with chronic liver disease. <i>BMJ Open</i> , <b>2015</b> , 5, e007451	3	42
80	The development and evaluation of an oncological palliative care deprescribing guideline: the OncPal deprescribing guideline. <i>Supportive Care in Cancer</i> , <b>2015</b> , 23, 71-8	3.9	71
79	Using the apparent diffusion coefficient to identifying MGMT promoter methylation status early in glioblastoma: importance of analytical method. <i>Journal of Medical Radiation Sciences</i> , <b>2015</b> , 62, 92-8	1.5	26
78	Factors associated with cancer-specific and overall survival among Indigenous and non-Indigenous gynecologic cancer patients in Queensland, Australia: a matched cohort study. <i>International Journal of Gynecological Cancer</i> , <b>2015</b> , 25, 542-7	3.5	10
77	Pharmacokinetics in neonatal prescribing: evidence base, paradigms and the future. <i>British Journal of Clinical Pharmacology</i> , <b>2015</b> , 80, 1281-8	3.8	38
76	Improving ambulatory patient-centred practice with a patient teaching associate programme. <i>Internal Medicine Journal</i> , <b>2015</b> , 45, 883-4	1.6	1
75	Polypharmacy among inpatients aged 70 years or older in Australia. <i>Medical Journal of Australia</i> , <b>2015</b> , 202, 373-7	4	64
74	The effects of tai chi in centrally obese adults with depression symptoms. <i>Evidence-based Complementary and Alternative Medicine</i> , <b>2015</b> , 2015, 879712	2.3	10
73	Reducing potentially inappropriate medications in palliative cancer patients: evidence to support deprescribing approaches. <i>Supportive Care in Cancer</i> , <b>2014</b> , 22, 1113-9	3.9	45
72	Toxicity and tolerability of adjuvant breast cancer chemotherapy in obese women. <i>Medical Oncology</i> , <b>2014</b> , 31, 881	3.7	18
71	A new frontier in haematology - combining pharmacokinetic with pharmacodynamic factors to improve choice and dose of drug. <i>British Journal of Clinical Pharmacology</i> , <b>2014</b> , 78, 274-81	3.8	7
70	Biomarker and imaging responses to spironolactone in subclinical diabetic cardiomyopathy. <i>European Heart Journal Cardiovascular Imaging</i> , <b>2014</b> , 15, 776-86	4.1	16
69	Diagnostic sensitivity of carbohydrate deficient transferrin in heavy drinkers. <i>BMC Gastroenterology</i> , <b>2014</b> , 14, 97	3	24
68	Fibronectin and transforming growth factor beta contribute to erythropoietin resistance and maladaptive cardiac hypertrophy. <i>Biochemical and Biophysical Research Communications</i> , <b>2014</b> , 444, 332-7	3.4	7
67	Longitudinal patterns of breast cancer screening: mammography, clinical, and breast self-examinations in a rural and urban setting. <i>Women's Health Issues</i> , <b>2014</b> , 24, e139-46	2.6	14

66	Aiming to be NEAT: safely improving and sustaining access to emergency care in a tertiary referral hospital. <i>Australian Health Review</i> , <b>2014</b> , 38, 564-74	1.8	42
65	Enabling the success of academic health science centres in Australia: where is the leadership?. <i>Medical Journal of Australia</i> , <b>2014</b> , 201, 636-8	4	2
64	Clinical research in synthetic cannabinoids - do we need a national approach?. <i>Medical Journal of Australia</i> , <b>2014</b> , 201, 317-9	4	3
63	Survival disparities in Australia: an analysis of patterns of care and comorbidities among indigenous and non-indigenous cancer patients. <i>BMC Cancer</i> , <b>2014</b> , 14, 517	4.8	51
62	Resveratrol does not benefit patients with nonalcoholic fatty liver disease. <i>Clinical Gastroenterology and Hepatology</i> , <b>2014</b> , 12, 2092-103.e1-6	6.9	198
61	Postprandial total and HMW adiponectin following a high-fat meal in lean, obese and diabetic men. <i>European Journal of Clinical Nutrition</i> , <b>2013</b> , 67, 377-84	5.2	21
60	Impact of dose-rate on the low-dose hyper-radiosensitivity and induced radioresistance (HRS/IRR) response. <i>International Journal of Radiation Biology</i> , <b>2013</b> , 89, 813-22	2.9	17
59	BMI but not stage or etiology of nonalcoholic liver disease affects the diagnostic utility of carbohydrate-deficient transferrin. <i>Alcoholism: Clinical and Experimental Research</i> , <b>2013</b> , 37, 1771-8	3.7	6
58	Deciding when to stop: towards evidence-based deprescribing of drugs in older populations. <i>Evidence-Based Medicine</i> , <b>2013</b> , 18, 121-4		75
57	Policy change to improve pathology turnaround time and reduce costs--possible to do both?. <i>Biochemia Medica</i> , <b>2013</b> , 23, 296-302	2.5	2
56	Khat-associated hepatitis. <i>Medical Journal of Australia</i> , <b>2013</b> , 199, 498-9	4	9
55	Smoking and drug interactions. <i>Australian Prescriber</i> , <b>2013</b> , 36, 102-104	1.4	16
54	Therapeutic drug monitoring to adjust dosing in morbid obesity - a new use for an old methodology. <i>British Journal of Clinical Pharmacology</i> , <b>2012</b> , 73, 685-90	3.8	28
53	Effect of obesity on toxicity in women treated with adjuvant chemotherapy for early-stage breast cancer: a systematic review. <i>Breast Cancer Research and Treatment</i> , <b>2012</b> , 136, 323-30	4.4	22
52	Minimizing inappropriate medications in older populations: a 10-step conceptual framework. <i>American Journal of Medicine</i> , <b>2012</b> , 125, 529-37.e4	2.4	79
51	Effects of a drug minimization guide on prescribing intentions in elderly persons with polypharmacy. <i>Drugs and Aging</i> , <b>2012</b> , 29, 659-67	4.7	7
50	Diamantina Health Partners: integrating leadership in research, research translation, education and clinical care. <i>Medical Journal of Australia</i> , <b>2012</b> , 196, 237-9	4	3
49	Therapeutic drug monitoring of antimicrobials. <i>British Journal of Clinical Pharmacology</i> , <b>2012</b> , 73, 27-36	3.8	197

48 Pharmacogenomics and Warfarin Therapy **2012**, 161-173

47 Target concentration intervention in oncology: where are we at?. *Therapeutic Drug Monitoring*, **2012**, 34, 257-65 3.2 17

46 Drug development: The use of unlicensed/off-label medicines in pediatrics. *Journal of Pediatric Gastroenterology and Nutrition*, **2012**, 55, 506-10 2.8 3

45 Ganciclovir pharmacokinetics and suggested dosing in continuous venovenous haemodiafiltration. *International Journal of Antimicrobial Agents*, **2011**, 37, 90-2 14.3 6

44 Reducing the burden of cancer for Aboriginal and Torres Strait Islander Australians: time for a coordinated, collaborative, priority-driven, Indigenous-led research program. *Medical Journal of Australia*, **2011**, 194, 530-1 4 17

43 Pitfalls of using estimations of glomerular filtration rate in an intensive care population. *Internal Medicine Journal*, **2011**, 41, 537-43 1.6 50

42 How reliable is eGFR when calculating drug dosage in acute medical admissions?. *Internal Medicine Journal*, **2011**, 41, 327-31 1.6 2

41 Incretin-based therapies--review of the physiology, pharmacology and emerging clinical experience. *Internal Medicine Journal*, **2011**, 41, 299-307 1.6 49

40 Resveratrol--pills to replace a healthy diet?. *British Journal of Clinical Pharmacology*, **2011**, 72, 27-38 3.8 81

39 Usefulness of at rest and exercise hemodynamics to detect subclinical myocardial disease in type 2 diabetes mellitus. *American Journal of Cardiology*, **2011**, 107, 615-21 3 24

38 Association of imaging markers of myocardial fibrosis with metabolic and functional disturbances in early diabetic cardiomyopathy. *Circulation: Cardiovascular Imaging*, **2011**, 4, 693-702 3.9 95

37 Scanning for safety: an integrated approach to improved bar-code medication administration. *CIN - Computers Informatics Nursing*, **2011**, 29, 157-64, quiz 165-6 1.4 8

36 Reduced end-systolic pressure-volume ratio response to exercise: a marker of subclinical myocardial disease in type 2 diabetes. *Circulation: Cardiovascular Imaging*, **2010**, 3, 443-9 3.9 17

35 The effect of a high-fat meal on postprandial arterial stiffness in men with obesity and type 2 diabetes. *Journal of Clinical Endocrinology and Metabolism*, **2010**, 95, 4455-9 5.6 18

34 Effect of atorvastatin on cardiac remodelling and mortality in rats following hyperglycemia and myocardial infarction. *International Journal of Cardiology*, **2010**, 143, 353-60 3.2 6

33 Comparison of a Commonwealth-initiated regional radiation oncology facility in Toowoomba with a Queensland Health facility. *Journal of Medical Imaging and Radiation Oncology*, **2010**, 54, 368-74 1.7

32 Assessment of nonischemic myocardial fibrosis. *Journal of the American College of Cardiology*, **2010**, 56, 89-97 15.1 166

31 Acidosis in the hospital setting: is metformin a common precipitant?. *Internal Medicine Journal*, **2010**, 40, 342-6 1.6 8

30	Stability of plasma creatinine concentrations in acute complex long-stay admissions to a general medical service. <i>Clinical Medicine</i> , <b>2010</b> , 10, 540-3	1.9	5
29	Current status of therapeutic drug monitoring in Australia and New Zealand: a need for improved assay evaluation, best practice guidelines, and professional development. <i>Therapeutic Drug Monitoring</i> , <b>2010</b> , 32, 615-23	3.2	28
28	Drug Use Evaluation Services in Australia and New Zealand: a Neglected Area of Research?. <i>Journal of Pharmacy Practice and Research</i> , <b>2010</b> , 40, 15-18	0.7	
27	Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. <i>Breast Cancer Research and Treatment</i> , <b>2010</b> , 123, 627-35	4.4	638
26	Marked increase in proton pump inhibitors use in Australia. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2010</b> , 19, 1019-24	2.6	84
25	Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society Of Infectious Diseases Pharmacists. <i>Clinical Biochemist Reviews</i> , <b>2010</b> , 31, 21-4	7.3	88
24	Using routine inpatient data to identify patients at risk of hospital readmission. <i>BMC Health Services Research</i> , <b>2009</b> , 9, 96	2.9	72
23	Association of diabetes with survival among cohorts of Indigenous and non-Indigenous Australians with cancer. <i>Cancer Causes and Control</i> , <b>2009</b> , 20, 355-60	2.8	12
22	Guidelines or external regulation?. <i>Internal Medicine Journal</i> , <b>2009</b> , 39, 789-91	1.6	1
21	Old bugs new populations: an unusual presentation of pericarditis. <i>Internal Medicine Journal</i> , <b>2009</b> , 39, 850-1	1.6	0
20	Rapidly Progressive Severe Amiodarone-Induced Hypothyroidism in an Elderly Female. <i>Journal of Pharmacy Practice and Research</i> , <b>2009</b> , 39, 140-141	0.7	
19	Role of statins in diabetes complications. <i>Current Diabetes Reviews</i> , <b>2009</b> , 5, 165-70	2.7	8
18	Doctors and the pharmaceutical industry: time for a national policy?. <i>Medical Journal of Australia</i> , <b>2009</b> , 191, 189-90	4	
17	eGFR--use beyond the evidence. <i>Medical Journal of Australia</i> , <b>2009</b> , 190, 197-9	4	17
16	Comment on "Quality of drug interaction alerts in prescribing and dispensing software". <i>Medical Journal of Australia</i> , <b>2009</b> , 191, 358; author reply 358-9	4	35
15	Statins and congestive heart failure. <i>Current Atherosclerosis Reports</i> , <b>2008</b> , 10, 369-76	6	1
14	Novel Drug Treatments for Hypertension <b>2007</b> , 1049-1060		1
13	Tranilast attenuates diastolic dysfunction and structural injury in experimental diabetic cardiomyopathy. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , <b>2007</b> , 293, H2860-9	5.2	50

12	Functional, structural and molecular aspects of diastolic heart failure in the diabetic (mRen-2)27 rat. <i>Cardiovascular Research</i> , <b>2007</b> , 76, 280-91	9.9	64
11	Statins and clinical outcomes in heart failure. <i>Clinical Science</i> , <b>2007</b> , 113, 119-27	6.5	20
10	In vitro inhibitory effects of atorvastatin on cardiac fibroblasts: implications for ventricular remodelling. <i>Clinical and Experimental Pharmacology and Physiology</i> , <b>2005</b> , 32, 697-701	3	52
9	Tranilast attenuates cardiac matrix deposition in experimental diabetes: role of transforming growth factor-beta. <i>Cardiovascular Research</i> , <b>2005</b> , 65, 694-701	9.9	84
8	Fibrosis as a therapeutic target post-myocardial infarction. <i>Current Pharmaceutical Design</i> , <b>2005</b> , 11, 477-87	3.7	44
7	Cytochrome P450 drug interactions within the HMG-CoA reductase inhibitor class: are they clinically relevant?. <i>Drug Safety</i> , <b>2003</b> , 26, 13-21	5.1	37
6	Severe hyperkalaemia with prescription of potassium-retaining agents in an elderly patient. <i>New Zealand Medical Journal</i> , <b>2003</b> , 116, U542	0.8	3
5	Altered sympathetic and parasympathetic activity in lung transplantation patients at rest and following autonomic perturbation. <i>Chest</i> , <b>2002</b> , 122, 1192-9	5.3	19
4	Role of valsartan and other angiotensin receptor blocking agents in the management of cardiovascular disease. <i>Pharmacological Research</i> , <b>2002</b> , 46, 203-12	10.2	20
3	Is cytochrome P450 2C9 genotype associated with NSAID gastric ulceration?. <i>British Journal of Clinical Pharmacology</i> , <b>2001</b> , 51, 627-30	3.8	41
2	The HEART FAILURE Journal Club: a review of publications on heart failure in American Heart Journal. <i>European Journal of Heart Failure</i> , <b>2001</b> , 3, 125-137	12.3	1
1	Cytochrome P450 drug interactions: are they clinically relevant?. <i>Australian Prescriber</i> , <b>2001</b> , 24, 10-12	1.4	8